DanCann Pharma A/S: Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™
COPENHAGEN, Denmark, 03 September 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma”) hereby on behalf of Tetra Bio-Pharma Inc. (“Tetra”), announce that Tetra Bio-Pharma - a leader in cannabinoid-derived drug discovery and development – yesterday announced that Tetra has received the Scientific Advice Assessment (SAA) Report from the Malta Medicines Authority.DanCann Pharma signed May 5th a definitive distribution agreement with Canadian Tetra Bio-Pharma Inc. concerning the exclusive distribution of the cannabinoid-based medicines Reduvo™ Adversa® and Qixleef™ in Denmark, Norway,